HUMAN INSIGHTS
PRECISION IMMUNOTHERAPY
Immunitas is committed to discovering and developing novel, differentiated therapeutics for patients with cancer. Our discovery engine combines deep expertise in single-cell genomics with customized machine learning approaches to elucidate immune cell populations that are key actors in immuno-oncology. Immunitas complements this process with bespoke in-house therapeutic discovery rooted in antibody display and immunization. Through our fully integrated internal R&D capabilities and parallel discovery efforts, we are accelerating the timeline from discovery to the clinic. Our lead program for solid tumor and hematological malignancies is currently in clinical trials.
TEAM
Our highly experienced management team, Board of Directors, and Scientific Advisory Board have a demonstrated track record of scientific progression. We are committed to the growth and success of our employees. We believe that high-functioning teams thrive when facing scientific challenges, and as a result we place high value on team members who are both innovative and collaborative.
We are scientific explorers committed to fostering a culture of innovation at each step of the drug development process. Join us as we explore the frontiers of novel biology.
OUR BIOLOGY
Immunitas was founded by a team of highly renowned cancer research and therapeutic antibody pioneers from Dana Farber Cancer Institute, Mass General Cancer Center, the Broad Institute, and MIT. They believe the best way to identify therapeutics for patients is to systematically interrogate the human biology. Immunitas has held true to that approach, and our research hypotheses are formed and tested using human tumor samples and primary cells. Our focus on human data allows us to start with and stay closer to the most relevant and translatable biology for patients and accelerate the pace of our research. We have a track record of identifying novel, exciting immuno-oncology targets and we prioritize the development of relevant biomarkers to guide the selection of patients who may benefit from our new drugs in future studies. This is further aided by our strong internal expertise in antibody discovery and engineering, which enables parallel discovery and advancement of therapeutic antibodies.
PIPELINE
Immunitas is building a robust pipeline of highly differentiated immuno-oncology antibody-based therapeutics. We are advancing our wholly owned development candidate, IMT-009 (a-CD161 mAb), through clinical evaluation. IMT-009 shows potential efficacy for monotherapy and combination treatment for solid tumors and hematological malignancies.
NEWS & EVENTS
November 16, 2021
JOIN US
Full-time Opportunities
Immunitas is hiring passionate leaders, scientists, and development specialists to join our team of high-performance employees that are excited by the pursuit of novel biology. Please contact us at info@immunitastx.com for more information.
In addition to a competitive benefits package including healthcare and paid time off, Immunitas also offers the following:
Company-wide shutdown between Christmas and New Years
5 week paid sabbatical after 5 years of employment
$5,000 tuition reimbursement for career development
Paid parental leave
Internship and Cooperative Programs
We are committed to providing meaningful, goal-oriented internship and co-op programs to both undergraduate and graduate students. We welcome applicants from the biology, computer and laboratory science disciplines, as well as from finance, marketing, and business development who would like to join the mission.
Many members of the Immunitas team, including our CEO, benefited from strong internship experiences and we are committed to providing a strong learning and growth experience. Interns are integrated with the team, have access to company leadership, and will gain valuable scientific and business experience.
